Determination of antiparkinsonism drug entacapone

Nashwah Gadallah Mohamed, Mohamed Sultan Mohamed

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Spectrophotometric procedures are presented for the determination of the antiparkinsonism drug entacapone. The first method based on the formation of a coloured complex of entacapone with ferric chloride in ethanolic solutions. The coloured product is quantified spectrophotometrically at 665nm. The other Spectrophotometric method determine entacapone in presence of levodopa and carbidopa (which formulated with entacapone in stalevo tablets) by measuring the UV absorbance of entacapone either in zero order at 391nm or in the first order by measuring the amplitude between 360nm and 402nm without any interference from levodopa and carbidopa. HPLC method is described for the separation and determination of entacapone, levodopa and carbidopa on Luna CN 150 × 4.6 column with UV detection at 390nm for entacapone and at 280nm for both levodopa and carbidopa.

Original languageEnglish
Pages (from-to)85-89
Number of pages5
JournalJournal of the Chilean Chemical Society
Volume55
Issue number1
Publication statusPublished - 21 May 2010

Fingerprint

Pharmaceutical Preparations
entacapone
Tablets
levodopa drug combination carbidopa

Cite this

@article{e0618e2983e44fa18e4f278a6e83cd47,
title = "Determination of antiparkinsonism drug entacapone",
abstract = "Spectrophotometric procedures are presented for the determination of the antiparkinsonism drug entacapone. The first method based on the formation of a coloured complex of entacapone with ferric chloride in ethanolic solutions. The coloured product is quantified spectrophotometrically at 665nm. The other Spectrophotometric method determine entacapone in presence of levodopa and carbidopa (which formulated with entacapone in stalevo tablets) by measuring the UV absorbance of entacapone either in zero order at 391nm or in the first order by measuring the amplitude between 360nm and 402nm without any interference from levodopa and carbidopa. HPLC method is described for the separation and determination of entacapone, levodopa and carbidopa on Luna CN 150 × 4.6 column with UV detection at 390nm for entacapone and at 280nm for both levodopa and carbidopa.",
author = "Mohamed, {Nashwah Gadallah} and Mohamed, {Mohamed Sultan}",
year = "2010",
month = "5",
day = "21",
language = "English",
volume = "55",
pages = "85--89",
journal = "Journal of the Chilean Chemical Society",
issn = "0717-9324",
publisher = "Sociedad Chilena De Quimica",
number = "1",

}

Determination of antiparkinsonism drug entacapone. / Mohamed, Nashwah Gadallah; Mohamed, Mohamed Sultan.

In: Journal of the Chilean Chemical Society, Vol. 55, No. 1, 21.05.2010, p. 85-89.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Determination of antiparkinsonism drug entacapone

AU - Mohamed, Nashwah Gadallah

AU - Mohamed, Mohamed Sultan

PY - 2010/5/21

Y1 - 2010/5/21

N2 - Spectrophotometric procedures are presented for the determination of the antiparkinsonism drug entacapone. The first method based on the formation of a coloured complex of entacapone with ferric chloride in ethanolic solutions. The coloured product is quantified spectrophotometrically at 665nm. The other Spectrophotometric method determine entacapone in presence of levodopa and carbidopa (which formulated with entacapone in stalevo tablets) by measuring the UV absorbance of entacapone either in zero order at 391nm or in the first order by measuring the amplitude between 360nm and 402nm without any interference from levodopa and carbidopa. HPLC method is described for the separation and determination of entacapone, levodopa and carbidopa on Luna CN 150 × 4.6 column with UV detection at 390nm for entacapone and at 280nm for both levodopa and carbidopa.

AB - Spectrophotometric procedures are presented for the determination of the antiparkinsonism drug entacapone. The first method based on the formation of a coloured complex of entacapone with ferric chloride in ethanolic solutions. The coloured product is quantified spectrophotometrically at 665nm. The other Spectrophotometric method determine entacapone in presence of levodopa and carbidopa (which formulated with entacapone in stalevo tablets) by measuring the UV absorbance of entacapone either in zero order at 391nm or in the first order by measuring the amplitude between 360nm and 402nm without any interference from levodopa and carbidopa. HPLC method is described for the separation and determination of entacapone, levodopa and carbidopa on Luna CN 150 × 4.6 column with UV detection at 390nm for entacapone and at 280nm for both levodopa and carbidopa.

UR - http://www.scopus.com/inward/record.url?scp=77952402898&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 85

EP - 89

JO - Journal of the Chilean Chemical Society

JF - Journal of the Chilean Chemical Society

SN - 0717-9324

IS - 1

ER -